| Literature DB >> 32161658 |
Sharon Kaasalainen1,2, Paulette V Hunter3, Vanina Dal Bello-Haas4, Lisa Dolovich2,5,6, Katherine Froggatt7, Thomas Hadjistavropoulos8, Maureen Markle-Reid9, Jenny Ploeg10, Joyce Simard11, Lehana Thabane6, Jenny T van der Steen12, Ladislav Volicer13.
Abstract
BACKGROUND: Residents living and dying in long-term care (LTC) homes represent one of society's most frail and marginalized populations of older adults, particularly those residents with advanced dementia who are often excluded from activities that promote quality of life in their last months of life. The purpose of this study is to evaluate the feasibility, acceptability, and effects of Namaste Care: an innovative program to improve end-of-life care for people with advanced dementia.Entities:
Keywords: Dementia; Long-term care; Palliative care
Year: 2020 PMID: 32161658 PMCID: PMC7053118 DOI: 10.1186/s40814-020-00575-4
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Sample characteristics at baseline, N = 31
| Variable | Descriptive statistic |
|---|---|
| Age (years), mean (SD) | 86.4 (9.3) |
| Gender, | |
| Male | 4 (12.9) |
| Female | 27 (87.1) |
| Marital status, | |
| Single | 2 (6.7) |
| Married | 8 (26.7) |
| Divorced | 1 (3.3) |
| Widow | 19 (63.3) |
| Length of stay (years), mean (SD) | 3.5 (3.8) |
| Charlson Comorbidity Index (CCI), mean (SD) | 4.3 (1.7) |
| Rheumatic or connective tissue disease, | 22 (71.0) |
| Hypertension, | 21 (67.7) |
| Depression, | 11 (35.5) |
| Cerebrovascular disease, | 7 (22.6) |
| Previous myocardial infarction, | 6 (19.4) |
| Congestive heart failure, | 5 (16.1) |
| Diabetes mellitus, | 5 (16.1) |
| Peripheral vascular disease, | 3 (9.7) |
| Warfarin use, | 3 (9.7) |
| Skin ulcers, | 3 (9.7) |
| Pulmonary disease, | 2 (6.5) |
| Renal disease, | 2 (6.5) |
SD standard deviation
Feasibility indicators
| Indicator | Study result | Pre-set criteria for success of feasibility |
|---|---|---|
| Participation rate | 88.6% | > 80% consent who are eligible |
| Percentage of sessions attended per week | 71.8% | At least 80% (8/10/week) |
| Average length of session | 1.95 h | > 1.5 h |
Retention rate: 3 months | 90.3% (three died before 3 months) | 90% have at least 3 months of data collection completed |
| Safety | 10% ( | No major injuries or adverse events reported (0%) |
Fig. 1Intervention flow diagram
Intervention fidelity: mean percentage (%) of residents who received activity at each session
| Program component | Meana (standard deviation) |
|---|---|
| Appears awake | 83 (0.15) |
| Music | 83 (0.15) |
| Massage | 67 (0.13) |
| Drank beverage | 62 (0.19) |
| Hair brushed | 55 (0.11) |
| Range of motion | 38 (0.12) |
| Scents | 44 (0.16) |
| Pain assessment | 24 (0.13) |
| Movie | 18 (0.17) |
| Reading | 18 (0.16) |
| Feet washed | 11 (0.11) |
| Family visits | 12 (0.14) |
aMean value was rounded to nearest whole number
Outcome measures at baseline and 6 months, N = 28
| Outcome measure | Baseline (T1) | 6 months (T2) | Baseline to 6 months (T2–T1) mean difference (SD) | 95% confidence interval | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Pain (PACSLAC-II) | 6.0 (5.0) | 5.3 (3.8) | − 0.7 (4.3) | 0.82 (0.42) | − 0.97 | 2.26 |
| Quality of life (QUALID) | 26.4 (8.9) | 24.7 (10.3) | − 1.7 (10.9) | 0.86 (0.40) | − 2.35 | 5.77 |
| Medication costs ($) | 64.8 (58.1) | 59.0 (52.5) | − 5.8 (53.6) | 1.21 (0.24) | − 4.01 | 15.59 |
| MQS benzodiazepine use | 0.3 (1.0) | 0.00 (0.0) | − 0.3 (1.0) | 1.44 (0.16) | − 0.12 | 0.68 |
| MQS antidepressant use | 2.9 (3.3) | 2.5 (3.3) | − 0.4 (3.3) | 1.89 (0.05) | 0.04 | 0.83 |
| MQS antipsychotic use | 1.4 (3.3) | 1.4 (2.8) | 0.0 (3.1) | 0.00 (1.00) | − 0.76 | 0.76 |
| MQS acetaminophen use | 3.1 (2.3) | 3.2 (2.5) | 0.1 (2.5) | − 0.63 (0.53) | − 0.76 | 0.40 |
| MQS NSAID use | 1.2 (2.7) | 1.1 (2.8) | − 0.1 (2.7) | 0.44 (0.66) | − 0.44 | 0.69 |
| MQS opioid use | 2.1 (3.1) | 2.8 (4.4) | 0.7 (4.5) | − 1.07 (0.30) | − 2.19 | 0.69 |
| MQS-III total score | 15.8 (11.6) | 15.1 (10.8) | − 0.7 (11.4) | 0.69 (0.49) | − 1.36 | 2.74 |
SD standard deviation, PACSLAC II Pain Assessment Checklist for Seniors with Limited Ability to Communicate, range 0–31; QUALID Quality of Life in Late-Stage Dementia, range 11–55, higher scores represent lower QOL; MQS medication quantification scale; NSAID non-steroidal anti-inflammatory drug